Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

"Soter Bio was built to support advanced therapeutic programs that depend on reliable, rapid, scalable input materials," said Mike Stewart, Founder and CEO of Soter Bio. "Partnering with Cellipont ...

How integrated pharmaceutical manufacturing helps CDMOs simplify scale-up, reduce complexity, and move from raw materials to finished dosage forms faster.

MUSCAT, FEB 23As Oman advances its ambitions under Oman Vision 2040, the spotlight is increasingly shifting from mere production to how ...

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in ...

Aras, a leading provider of digital thread solutions for product lifecycle management (PLM) and engineering AI, today announced an expanded cloud strategy for Aras Innovator that gives customers ...